Publications by authors named "Mark Sydenham"

Claim this Profile
B
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials.
Szeyi Ng, Anna M Kirby, Lucy S Kilburn, Clare Griffin, Mark Sydenham

Radiother Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.
Szeyi Ng, Lucy S Kilburn, Anna M Kirby, Clare Griffin, Mark Sydenham

Radiother Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.
Anna M Kirby, Laura Finneran, Clare L Griffin, Adrian M Brunt, Fay H Cafferty, Mark A Sydenham

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.
A Murray Brunt, Fay H Cafferty, Duncan Wheatley, Mark A Sydenham, Anna M Kirby

Radiother Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
Charlotte E Coles, Joanne S Haviland, Anna M Kirby, Clare Griffin, Mark Sydenham

Lancet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, David J Bloomfield

Health Technol Assess· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Christopher Nutting, Laura Finneran, Justin Roe, Mark A Sydenham, Matthew Beasley

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Charlotte E Coles, Joanne S Haviland, Anna M Kirby, Clare L Griffin, Mark A Sydenham

Lancet· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
Adrian Murray Brunt, Joanne S Haviland, Mark Sydenham, Rajiv K Agrawal, Hafiz Algurafi

J Clin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso

Lancet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
Christopher M Nutting, James P Morden, Matthew Beasley, Shreerang Bhide, Audrey Cook, Mark Sydenham

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.
Joanne S Haviland, Mariella Mannino, Clare Griffin, Nuria Porta, Mark Sydenham

Radiother Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
A Murray Brunt, Duncan Wheatley, John Yarnold, Navita Somaiah, Stephen Kelly, Mark Sydenham

Radiother Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late effects of breast radiotherapy.
Joanne S Haviland, Judith M Bliss, Mark Sydenham, John R Yarnold

Lancet· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy.
Charlotte B Westbury, Joanne Haviland, Sue Davies, Lone Gothard, Bahja Ahmed Abdi, Mark Sydenham

Radiat Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Joanne S Haviland, J Roger Owen, John A Dewar, Rajiv K Agrawal, Jane Barrett, Mark A Sydenham

Lancet Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?
Christy Goldsmith, Joanne Haviland, Yat Tsang, Mark Sydenham, John Yarnold

Radiother Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Radiother Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M Nutting, James P Morden, Kevin J Harrington, Teresa Guerrero Urbano, Shreerang A Bhide, Mark A Sydenham

Lancet Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy.
Susan Martin, Mark Sydenham, Joanne Haviland, Roger A'Hern, Roger Owen

Radiother Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis